In the high-stakes world of global healthcare, leadership demands scientific literacy, strategic clarity, and unwavering resilience. Few embody these qualities as powerfully as Belén Garijo. As the CEO of Merck KGaA, she has made history as the first woman to lead the 350-year-old German multinational. Her rise is not only a personal achievement but also a symbol of transformation in one of the world’s most influential science and technology companies.
From Medicine to Management
Born in Almansa, Spain, Belén Garijo originally trained as a physician. She earned her medical degree from the University of Alcalá and later specialized in clinical pharmacology. Her early career was rooted in patient care and scientific research—an experience that would shape her leadership philosophy for decades to come.
Garijo began her professional journey in the pharmaceutical sector with roles at Abbott Laboratories and later at Sanofi-Aventis. These formative years provided her with deep insight into drug development, regulatory frameworks, and the complex relationship between innovation and patient access. Unlike many corporate executives who approach healthcare from a purely financial or operational perspective, Garijo’s decisions are anchored in a clinician’s understanding of real-world impact.
Rising Through the Ranks at Merck
Garijo joined Merck in 2011, taking on leadership roles within its biopharmaceutical division. At the time, the company was undergoing strategic restructuring, seeking to sharpen its focus on high-growth areas such as oncology, immunology, and specialty medicine. Her ability to align scientific innovation with commercial strategy quickly set her apart.
By 2015, she became CEO of Merck’s Healthcare business sector. Under her leadership, the division strengthened its pipeline, invested in cutting-edge therapies, and expanded its global presence. She emphasized partnerships, research excellence, and patient-centric solutions, helping the company compete more effectively in a rapidly evolving pharmaceutical landscape.
In 2021, Garijo was appointed CEO of Merck KGaA, marking a historic milestone. The company, founded in 1668 and controlled by the Merck family for generations, had never before been led by a woman. Her appointment signaled not only trust in her strategic capabilities but also a broader cultural shift toward inclusivity and modern governance.
Balancing Innovation and Responsibility
At the helm of a global science and technology group operating across healthcare, life science, and electronics, Garijo oversees a vast portfolio that touches millions of lives. Her leadership philosophy revolves around three pillars: innovation, sustainability, and long-term value creation.
One of her primary goals has been accelerating research and development. She champions investment in breakthrough therapies, particularly in oncology and rare diseases, while ensuring the company remains competitive in fast-moving markets such as biotechnology and semiconductor materials.
At the same time, Garijo recognizes the ethical responsibility that accompanies scientific advancement. She has been vocal about equitable access to medicines, environmental sustainability, and responsible corporate governance. Under her leadership, Merck has strengthened its environmental, social, and governance (ESG) commitments, aligning profitability with purpose.
Navigating Global Challenges
Garijo assumed the CEO role during a period marked by global uncertainty. The COVID-19 pandemic had disrupted supply chains, reshaped healthcare priorities, and intensified competition across the pharmaceutical sector. Her experience and steady leadership helped Merck navigate these complexities while maintaining strategic focus.
She emphasizes resilience and adaptability, encouraging teams to embrace digital transformation and data-driven decision-making. The integration of advanced analytics, artificial intelligence, and innovative manufacturing processes has become central to Merck’s operational strategy.
Moreover, Garijo has advocated for stronger collaboration between industry, governments, and academic institutions. She believes that solving global health challenges—from pandemics to chronic diseases—requires coordinated efforts that transcend borders and sectors.
Championing Diversity and Inclusion
As one of the most prominent female CEOs in Europe, Garijo’s leadership carries symbolic weight. She often speaks about the importance of diversity in driving innovation. In her view, inclusive organizations are better equipped to generate creative solutions and navigate complex global markets.
Within Merck, she has promoted initiatives aimed at increasing gender representation in leadership roles and fostering inclusive workplace cultures. Her own journey—from medical doctor in Spain to CEO of a global German enterprise—demonstrates the value of cross-cultural experience and perseverance.
Garijo also serves on various advisory boards and participates in international forums where she contributes to discussions on healthcare policy, digital transformation, and corporate responsibility. Her voice resonates not only within the pharmaceutical industry but also in broader conversations about the future of global business leadership.
A Vision for the Future
Looking ahead, Garijo envisions Merck as a catalyst for scientific breakthroughs that address some of humanity’s most pressing challenges. From advancing personalized medicine to enabling next-generation electronics, the company’s diverse portfolio positions it at the intersection of health and technology.
She underscores the importance of long-term thinking in an era often dominated by short-term market pressures. Sustainable growth, she argues, stems from consistent investment in research, talent, and ethical governance.
Her medical background continues to influence her approach. For Garijo, success is not measured solely in quarterly earnings but in meaningful outcomes—improved patient lives, scientific progress, and environmental stewardship.
Redefining Leadership in Science
Belén Garijo’s ascent to the top of Merck KGaA represents more than corporate success; it reflects a broader transformation in how leadership is defined in science-driven industries. She blends clinical insight with strategic vision, compassion with competitiveness, and tradition with innovation.
In steering one of the world’s oldest pharmaceutical companies into a rapidly changing future, Garijo exemplifies modern executive leadership—grounded in expertise, guided by values, and committed to global impact. As healthcare and technology continue to converge, her influence will likely shape not only the trajectory of Merck but also the evolving standards of leadership in global science.
For more such articles, please follow us on Twitter, Linkedin & Instagram
Also Read:
Martine Rothblatt: Innovator shaping space, science, and identity
Kiran Mazumdar-Shaw: Biotech leader who took India global
Roshni Nadar Malhotra: Leading a New Global Tech Era
